Author of

• 25955

  +

  P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27444

    +

    P3.01-86 - Treatment Outcomes with Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients with Advanced NSCLC (ID 12784)

    12:00 - 13:30  |  Author(s): Austin Miller
    • Abstract
    • Slides

    Background
    

    Nivolumab (Nivo) was approved as second-line therapy in 2015 for patients (pts) with advanced NSCLC. The optimal effective interval between doses is not well-established. We want to evaluate the effect of reduced dose density on the efficacy and safety of Nivolumab.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    This is a single-institution, IRB approved retrospective review of stage IIIB/IV NSCLC who received Nivo after prior platinum-based chemotherapy in the second line setting or beyond between April 2015-January 2018. Characteristics of pts who received Nivo 240mg every(q) 4 weeks or longer, reasons for alternate dosing and their treatment outcomes are described.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Out of 181 pts with NSCLC who received Nivo during this time frame, 32 pts (18Male:14 Female) received an alternate dosing schedule (median q 4 weeks, range q 3-12 weeks). Median age was 65 years. Majority were former smokers (62%) and had adenocarcinoma (81%). 17 pts started on a regular schedule q 2 weeks and then switched to an alternate schedule, the remaining 15 pts started on an alternate schedule. 28% (9/32) patients were on an alternate schedule due to adverse event. Median expected total cumulative dose (240mg*no. of expected doses until disease progression or death) per pt is 4032mg (range 480 -15840). Median actual cumulative dose (240mg*actual no. of doses) received per pt is 1920mg (range 480 - 10560). This represents a median of 52% of the expected total cumulative dose received. Objective response rate (CR+PR) in the entire cohort was 66%. Median progression-free survival(PFS) from start of alternate schedule is 17.1 months (95% CI 5.2- not reached). 6-month PFS is 65% (95% CI 46%-79%) starting from when alternate schedule of Nivo was begun. We will present updated toxicity and treatment outcomes in the meeting.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Nivolumab 240mg administered at q 4 weeks or longer is feasible. Further investigation is needed to optimize patient selection for alternate dosing schedule.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.